RxDoctor Payments Data

Ilan Kedan, MD

Interventional Cardiology · Beverly Hills, CANPI 1689629057

Payments from drug & device makers

$1,493in general payments, 2019–2025

Across 56 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$232
  • AbbVie$165
  • Regeneron Healthcare Solutions, Inc.$142
  • Madrigal Pharmaceuticals$129
  • Alnylam Pharmaceuticals Inc.$111
  • Novo Nordisk$103
  • plus $612 from 12 others

What the payments were for

  • Food & beverage$1,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,493 in reported general payments places this provider in the 15th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$52,713
Medicare patients
238
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$148,730
XareltoRivaroxaban79$111,227
Praluent PenAlirocumab77$52,099
Repatha SureclickEvolocumab42$42,900
OzempicSemaglutide35$41,407
FarxigaDapagliflozin Propanediol44$39,112
EntrestoSacubitril/Valsartan35$26,177
JardianceEmpagliflozin17$16,262
WegovySemaglutide11$14,397
NorvascAmlodipine Besylate13$4,035
Rosuvastatin Calcium224$4,010
Metoprolol Succinate282$3,586
Atorvastatin Calcium239$2,664
Ezetimibe45$2,028
Amlodipine Besylate261$2,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$148,730130 claims
Novo NordiskOzempic, Wegovy$103$55,80446 claims
AstraZenecaFarxiga$29$39,11244 claims
NovartisEntresto$53$26,17735 claims
Boehringer IngelheimJardiance$88$16,26217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →